ArticleTherapeutic advances in musculoskeletal disease2022
Normal C-reactive protein in active psoriatic arthritis: results from real-world clinical practice.
Article in Therapeutic advances in musculoskeletal disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 21 citations in OpenAlex.
- CRP at diagnosis in psoriatic arthritis: what it means and associations with long-term outcomes.Rheumatology (Oxford, England) · 2026Article
- The effect of biologic disease modifying anti-rheumatic drugs on the neutrophil-lymphocyte ratio in psoriatic arthritis patients.Clinical rheumatology · 2026Observational
- The Role of Musculoskeletal Ultrasound in Psoriatic Arthritis: From Preclinical Detection to Treatment Monitoring.Current rheumatology reports · 2026Review
- Diagnostic delay in the early phase of psoriatic arthritis is independently associated with adverse pain-related cognitive responses: a multicentre cross-sectional study.Frontiers in immunology · 2026Article
- Article
- Therapeutic strategy in psoriatic arthritis: choosing the right treatment for the right patient.Therapeutic advances in musculoskeletal disease · 2025Article
- Study of the Gut Microbiome in Patients with Psoriatic Arthritis.European journal of rheumatology · 2024Article
- Sex-specific differences in patients with psoriatic arthritis:a nationwide study from the Chinese Registry of Psoriatic Arthritis (CREPAR IV).Clinical rheumatology · 2024Article
- Synergistic effect of periodontitis and C-reactive protein levels on mortality: NHANES 2001-2004.PloS one · 2024Article
- Prevalence of psoriatic arthritis in Italy: insights from the multicentric MAPSI study.Frontiers in medicine · 2024Article
- Type-I interferon pathway and DNA damage accumulation in peripheral blood of patients with psoriatic arthritis.Frontiers in immunology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The value of normal C-reactive protein (CRP) in psoriatic arthritis (PsA) is debatable. Objectives: To test the hypothesis that CRP is frequently normal in contemporary real-world PsA patients, despite active disease. Design: In this cross-sectional study, patients were divided into two groups: CRP ⩽ 0.5 mg/dl (normal) and CRP > 0.5 mg/dl (increased). Having as dependent variable the CRP status, these groups were compared for disease-related features, including composite disease activity indices [clinical Disease Activity in PSoriatic Arthritis (cDAPSA) and minimal disease activity (MDA)] and patient-reported outcomes (PROs). Agreement between CRP status and cDAPSA/MDA scores was calculated (Cohen's kappa). Methods: Data from consecutive PsA patients attending two outpatient rheumatology clinics (January 2019-June 2021) were analysed. Results: From 128 patients enrolled (51.6% females; mean ± standard deviation age: 53.4 ± 11.7 years; 23.4%, 48.4% and 64.1% treated with glucocorticoids, conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) and biologic DMARDs, respectively), two-thirds (66.4%, Conclusion: Normal CRP in PsA should not be used as surrogate marker of remission or low/MDA, therefore needs to be interpreted with caution in clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.